Managed care implications of age-related ocular conditions

American Journal of Managed Care

Volumn 19, Issue 5 SUPPL., 2013, Pages

  Cardarelli, William J ^a   Smith, Roderick A ^a  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ARTIFICIAL TEAR; BEVACIZUMAB; CYCLOSPORIN; LATANOPROST; PROSTAGLANDIN; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AWARENESS; BABY BOOMER; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASES; DRY EYE; EARLY INTERVENTION; EYE DISEASE; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SERVICE; HOME HEALTH AGENCY; HUMAN; INTRAOCULAR PRESSURE; JOB PERFORMANCE; MANAGED CARE; MANAGED CARE ORGANIZATION; MEDICAL CARE; MEDICARE; MEDICATION COMPLIANCE; NURSING HOME; OPEN ANGLE GLAUCOMA; OPTICAL COHERENCE TOMOGRAPHY; PATIENT; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PRESCRIPTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; SOCIAL ISOLATION; SYMPTOM; UNITED STATES; VISUAL ACUITY; VISUAL DISORDER; VISUAL IMPAIRMENT; AGED; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG COST; ECONOMICS; EXUDATIVE MACULAR DEGENERATION; LOW LEVEL LASER THERAPY; SEVERITY OF ILLNESS INDEX; ANTAGONISTS AND INHIBITORS; DRY EYE SYNDROMES; GLAUCOMA, OPEN-ANGLE; WET MACULAR DEGENERATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DIABETIC RETINOPATHY; DRUG COSTS; DRY EYE SYNDROMES; GLAUCOMA, OPEN-ANGLE; HUMANS; LASER THERAPY; MEDICARE; MEDICATION ADHERENCE; SEVERITY OF ILLNESS INDEX; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS; WET MACULAR DEGENERATION;

EID: 84894424003     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Crews JE, Campbell VA. Health conditions, activity limitations, and participation restrictions among older people with visual impairments. J Vis Impair Blind. 2001;105(August):453-467. (Pubitemid 32747560)
2. Crews JE, Jones GC, Kim JH. Double jeopardy: the effects of comorbid conditions among older people with vision loss. J Vis Impair Blind. 2006;100(special suppl):824-848.
3. Prevent Blindness America. The economic impact of vision problems: the toll of major adult eye disorders, visual impairment and blindness on the U.S. economy. http://www.preventblindness.net/site/DocServer/Impact-of-Vision- Problems.pdf. Published 2007. Accessed April 26, 2013.
4. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754-1760. (Pubitemid 44920172)
5. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol. 2007;125(4):544-550. (Pubitemid 46596727)
6. Friedman DS, Wolfs RC, O'Colmain BJ, et al; Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004; 122(4):532-538. (Pubitemid 38456289)
7. Lam BL, Zheng DD, Davila EP, et al. Trends in glaucoma medication expenditure: Medical Expenditure Panel Survey 2001-2006. Arch Ophthalmol. 2011;129(10):1345-1350.
8. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of glaucoma. Arch Ophthalmol. 2006;124(1):12-19. (Pubitemid 43063883)
9. Bramley T, Peeples P, Walt JG, Juhasz M, Hansen JE. Impact of vision loss on costs and outcomes in Medicare beneficiaries with glaucoma. Arch Ophthalmol. 2008;126(6):849-856. (Pubitemid 351831337)
10. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J; Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatements. Arch Ophthalmol. 2009;127(4):533-540.
11. Mitchell P, Annemans L, White R, Gallagher M, Thomas S. Cost effectiveness for treatments for wet age-related macular degeneration. Pharmacoeconomics. 2011;29(2):107-131.
12. CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
13. IVAN Study Investigators; Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-1411.
14. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.
15. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. N Engl J Med. 2011;364(20):1966-1967.
16. Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. J Eval Clin Practice. 2012;18(2):247-255.
17. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007;91(9):1244-1246. (Pubitemid 47344908)
18. Neumann PJ, Weinstein MC. Legislating against use of costeffectiveness information. N Engl J Med. 2010;363(16):1495-1497.
19. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti- VEGF drug. Br J Ophthalmol. 2012;96(9):1157-1158.
20. Shea AM, Curtis LH, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol. 2008;126(12):1748-1754.
21. Smiddy WE. Economic considerations of macula edema therapies. Ophthalmology. 2011;118(9):1827-1833.
22. Smiddy WE. Clinical applications of cost analysis of diabetic macular edema treatments. Ophthalmology. 2012;119(12):2558-2562.
23. Dewan V, Lambert D, Edler J, Kymes S, Apte RS. Costeffectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2012;119(8):1679-1684.
24. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
25. Do DV, Nguyen QD, Boyer D, et al; DA VINCI Study Group. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658-1665.
26. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-month data: report 2. Ophthalmology. 2010;117(6):1078-1086.
27. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379-387.
28. Galor A, Zheng DD, Arheart KL. Dry eye medication use and expenditures: data from the medical expenditure survey panel 2001 to 2006. Cornea. 2012;31(12):1403-1407.
29. Fiscella RG, Lee JT, Walt JG, Killian TD. Utilization characteristics of topical cyclosporine and punctal plugs in a managed care database. Am J Manag Care. 2008;14(3 suppl):S107-S112. (Pubitemid 351656968)
30. Age-Related Eye Disease: Opportunities for Managed Care Pharmacy. Live meeting coverage. The American Journal of Managed Care website. http://www.ajmc.com/conferences/AMCP-Fall-2012/Age-Related-Eye-Disease- Opportunities-for-Managed-Care-Pharmacy. Accessed April 26, 2013.
31. Xalatan goes generic: a landmark event in glaucoma. Glaucoma Today website. http://bmctoday.net/glaucomatoday/2011/06/article.asp?f=xalatan-goes- generic-a-landmark-event-inglaucoma. Accessed April 26, 2013.